Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research

Contract Research

Prana partners with Takeda in Parkinson’s gastrointestinal neuropathology Prana Biotechnology has entered into a research collaboration with Takeda Pharmaceuticals International to study the potential of its investigational movement disorders compound, PBT434, to slow or prevent neurodegeneration of the gastrointestinal system.
Contract Research & Services > Contract Research > News
Erytech, Queen’s University to advance eryminase program Erytech Pharma and the Queen’s University in Canada have entered into a research collaboration to advance the preclinical development of the former’s eryminase program specifically for the treatment of arginase-1 deficiency.
Contract Research & Services > Contract Research > News Daiichi Sankyo, Max Planck and Lead Discovery enter into cancer research collaboration Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have inked an agreement offering Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for cancer treatment to be discovered and developed at the Lead Discovery Center.
Contract Research & Services > Contract Research > News
See more Contract Research news

Latest Contract Research News and Insight

View all Contract Research news or find news targeted to your interests
Erytech, Queen’s University to advance eryminase program
Erytech Pharma and the Queen’s University in Canada have entered into a research collaboration to advance the preclinical development of the former’s eryminase program specifically for the treatment of arginase-1 deficiency.
Contract Research & Services > Contract Research > News
World Courier: World Courier Ground Europe
Specialized ground shipping for ground-breaking products.
Contract Research & Services > Contract Research > Products
World Courier: Pharmaceutical Storage and Distribution
Supply chain optimization and operational efficiency demand more than just safe and timely transport. World Courier not only ensures products and samples are delivered on time and in optimal condition, we also provide the clinical development community with services that enhance the performance of their R&D investments.
Contract Research & Services > Contract Research > Products
World Courier: Personalized Supply Chain – Direct-to-Patient
A major challenge running clinical trials is patient recruitment and retention; in order to participate, patients must often be willing to travel long distances at inconvenient times to undergo treatment and vital procedures, a situation that is certain to lead to frustration all round.
Contract Research & Services > Contract Research > Products
World Courier: Cocoon
Today’s logistics environment grows more complex as demand for time-sensitive and temperature-sensitive transport increases while resources are scarce. We drive improvement in this transitioning market with innovation, value creation and flawless execution.
Contract Research & Services > Contract Research > Products
World Courier: Cell and Gene Therapy
Cell and Gene Therapies have demonstrated real promise as they move into the clinical trial phase for a variety of life changing and deadly diseases.
Contract Research & Services > Contract Research > Products
Daiichi Sankyo, Max Planck and Lead Discovery enter into cancer research collaboration
Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have inked an agreement offering Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for cancer treatment to be discovered and developed at the Lead Discovery Center.
Contract Research & Services > Contract Research > News
Almac Discovery is Granted Orphan Drug Designation for ALM201 Programme in Ovarian Cancer
Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate ALM201 in the treatment of ovarian cancer.
Contract Research & Services > Contract Research > Press Releases
Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
– Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA, a Switzerland based speciality pharma company, today announced a collaboration to pursue the development of Almac Discovery’s Wee-1 kinase inhibitor programme.
Contract Research & Services > Contract Research > Press Releases
View all Contract Research news or find news targeted to your interests